FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Legorreta Pablo G.
(Last) (First) (Middle)
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Chairman of the Board
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Shares 08/05/2026   A   65,216 (1) A $ 0 1,307,820 D  
Class A Ordinary Shares               1,040,410 I By Legorreta Children 2002 Trust
Class A Ordinary Shares               901,590 I By GST-Exempt Legorreta 2012 Family Trust
Class A Ordinary Shares               600,000 I By Legorreta 2023 SR Trust
Class A Ordinary Shares               460,139 I By Legorreta Investments LLC
Class A Ordinary Shares               292,190 I By Tata MC 35 Ltd.
Class A Ordinary Shares               123,310 I By IRRA
Class A Ordinary Shares               118,500 I By SEP/IRA
Class A Ordinary Shares               41,306 I By GST-Exempt Legorreta 2020 Family Trust
Class A Ordinary Shares               10,000 I By Son
Class A Ordinary Shares               10,000 I By Daughter
Class A Ordinary Shares               6,930 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
LP interests in RPI US Partners 2019, LP (2) 08/07/2026   G     30,000   (3)   (3) Class A Ordinary Shares 300,000 $ 0 662,701 D  
LP interests in RPI US Partners 2019, LP $ 0               (3)   (3) Class A Ordinary Shares 37,074,880   3,707,488 I By Legorreta Investments LLC
LP interests in RPI US Partners 2019, LP $ 0               (3)   (3) Class A Ordinary Shares 18,323,630   1,832,363 I By Legorreta Investments II LLC
LP interests in RPI US Partners 2019, LP $ 0               (3)   (3) Class A Ordinary Shares 1,470,140   147,014 I By Spouse
Explanation of Responses:
1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
2. No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
3. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Remarks:
In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold 9,700,000 Class B Ordinary Shares exchangeable into 9,700,000 Class A Ordinary Shares and 13,356,742 Class E Ordinary Shares of Holdings exchangeable into 13,356,742 Class A Ordinary Shares. Class E Ordinary Shares of Holdings are subject to vesting conditions.
/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 08/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.